|
|
|
| Clinical effect of Liraglutide combined with Metformin in the treatment of obese patients with type 2 diabetes mellitus |
| DING Xiao-hui |
| Department of Endoerinology,Changda Hospital of Anshan City,Liaoning Province,Anshan 114007,China |
|
|
|
|
Abstract Objective To explore the clinical effect of Liraglutide combined with Metformin in the treatment of obese patients with type 2 diabetes mellitus.Methods A total of 80 obese patients with type 2 diabetes treated in Changda Hospital of Anshan City from January to June 2019 were selected as the research objects.According to random number table method,they were divided into observation group and control group,with 40 cases in each group.Observation group was treated with Liraglutide combined with Metformin,and control group was treated with Metformin,both groups were treated for 3 months.Hemoglobin A1c(HbA1c),fasting blood glucose(FBG),2 hours postprandial blood glucose(2 h PG),Homeostasis model assessment of insulin resistance(HOMA-IR),Homeostasis model assessment-β(HOMA-β),body mass index(BMI)before and after treatment and the incidence of adverse reactions during treatment in the two groups were compared.Results After treatment,FBG,2 h PG,HbA1c,BMI and HOMA-IR in the two groups were lower than those before treatment,and HOMA-β was higher than that before treatment,the differences were statistically significant(P＜0.05).After treatment,FBG,2 h PG,HbA1c,BMI,HOMA-IR in observation group were lower than those in control group,and HOMA-β was higher than that in control group,the differences were statistically significant(P＜0.05).There was 1 case of gastrointestinal reaction in the observation group and 1 case in the control group,and there was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The Liraglutide combined with Metformin has obvious therapeutic effect on type 2 diabetes mellitus,which can effectively control blood glucose level,improve insulin function,promote insulin secretion,reduceinsulin resistance and BMI,with fewer adverse reactions,good safety.Therefore which has positive clinical significance.It is worth promoting.
|
|
|
|
|
|
| [1] |
严学琴，付春艳，雷雨.利拉鲁肽联合二甲双胍治疗肥胖合并2 型糖尿病患者脂代谢、胰岛β 细胞功能及体脂的影响探究[J].中华细胞与干细胞杂志，2019，9（5）：276-281.
|
| [2] |
林园，冯利.利拉鲁肽联合联合二甲双胍治疗老年2 型糖尿病患者血清Hcy，CysC，hs-CRP 水平及糖脂代谢的影响[J].中国老年学杂志，2020，40（3）：502-504.
|
| [3] |
郭洁，张玉，孙耀东，等.利拉鲁肽联合二甲双胍对糖尿病合并冠心病患者血清趋化素及胰岛素抵抗的影响[J].中国循证心血管杂志，2019，11（2）：212-214.
|
| [4] |
Kirkman MS，Mahmud H，Korytkowski MT.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus[J].Endocrinol Metab Clin North Am，2018，47（1）：81-96.
|
| [5] |
范可军.GLP-1 对2 型糖尿病合并肥胖患者糖脂代谢及体重的影响[J].包头医学院学报，2018，34（3）：72-73.
|
| [6] |
王艳妮，李转霞.二甲双胍联合利拉鲁肽对2 型糖尿病合并非酒精性脂肪肝患者胰岛B 细胞功能、肝功能及外周血Treg 细胞的影响[J].医学临床研究，2018，35（1）：11-14.
|
| [7] |
张建元，秦婷婷，尹平，等.二甲双胍与罗格列酮治疗2型糖尿病疗效和安全性的Meta 分析[J].华中科技大学学报（医学版），2018，47（1）：109-115.
|
| [8] |
曹义坡，李颖，吕晓楠，等.利拉鲁肽联合二甲双胍改善老年2 型糖尿病伴代谢综合征患者代谢参数及颈动脉内膜中层厚度效果分析[J].山西医药杂志，2020，49（7）：789-792.
|
| [9] |
张卫欢，李秋云，杨春伟，等.大柴胡汤加减联合利拉鲁肽对肥胖2 型糖尿病患者胰岛素抵抗、B-细胞功能和低度炎症反应的影响[J].现代中西医结合杂志，2018，27（1）：23-26，30.
|
| [10] |
贾真，何旺，张渭涛，等.利拉鲁肽联合二甲双胍在2 型糖尿病患者中的防治效果及对机体免疫的影响研究[J].陕西医学杂志，2018，47（1）：114-116.
|
| [11] |
程晨，刘丽楠，王静，等.利拉鲁肽联合二甲双胍治疗老年2 型糖尿病效果分析[J].中国医学前沿杂志（电子版），2018，10（4）：85-86.
|
| [12] |
林创辉，肖红刚.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观[J].临床合理用药杂志，2017，10（8）：41-42.
|
| [13] |
赵富利，亓民，刘辉.利拉鲁肽联合二甲双胍治疗2型糖尿病伴有肥胖患者疗效及对微炎症状态的影响[J].中国现代医学杂志，2015，25（15）：43-45.
|
| [14] |
高婷婷.不同糖耐量人群尿C 肽肌酐比值与胰岛β 细胞功能和胰岛素抵抗的关系研究[J].北华大学学报（自然科学版），2017，18（3）：352-355.
|
| [15] |
孙晓方，王越，赵文娟，等.利拉鲁肽对肥胖2 型糖尿病患者胰高血糖素分泌功能的影响[J].中华内科杂志，2019，58（1）：33-38.
|
|
|
|
